Get the Stockscreener App
7.62
2.83%
0.21
Regenxbio Inc stock is traded at $7.62, with a volume of 8.48M.
It is up +2.83% in the last 24 hours and down -20.87% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$7.41
Open:
$7.36
24h Volume:
8.48M
Relative Volume:
9.22
Market Cap:
$377.53M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.2057
EPS:
-6.32
Net Cash Flow:
$-194.72M
1W Performance:
-7.97%
1M Performance:
-20.87%
6M Performance:
-35.86%
1Y Performance:
-58.36%
1-Day Range:
$7.21
$7.75
1-Week Range:
$7.21
$8.75
52-Week Range:
$7.21
$28.80
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.62 | 377.53M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Stifel Financial Corp Boosts Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,880 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO to Participate in Upcoming Investor Conferences - Kilgore News Herald
BNP Paribas Financial Markets Purchases 17,533 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Trading (RGNX) With Integrated Risk Controls - Stock Traders Daily
REGENXBIO: A Hidden Gem in Gene Therapy with Promising Pipeline and Growth Potential - mediahousepress
REGENXBIO's SWOT analysis: gene therapy firm's stock poised for growth By Investing.com - Investing.com Australia
REGENXBIO's SWOT analysis: gene therapy firm's stock poised for growth - Investing.com India
National Bank of Canada FI Invests $713,000 in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Regenxbio stock hits 52-week low at $8.39 amid market challenges - Investing.com Australia
REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Royal Bank of Canada Reiterates “Outperform” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Where Regenxbio Stands With Analysts - Benzinga
Jacobs Levy Equity Management Inc. Trims Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - The Eastern Progress Online
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect - The Eastern Progress Online
Regenxbio stock touches 52-week low at $8.51 amid market challenges - Investing.com Canada
(RGNX) Trading Report - Stock Traders Daily
Regenxbio Updates Leadership, Names New CEO - Contract Pharma
REGENXBIO Inc. (NASDAQ:RGNX) is Redmile Group LLC's 10th Largest Position - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
How To Trade (RGNX) - Stock Traders Daily
HC Wainwright Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $36.00 - Defense World
REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital - Defense World
Regenxbio price target lowered to $36 from $40 at H.C. Wainwright - MSN
HC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat
Regenxbio starts pivotal trial testing DMD gene therapy RGX-202 - Muscular Dystrophy News
Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat
H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock - Investing.com Nigeria
H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock By Investing.com - Investing.com South Africa
Chardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
Regenxbio down 13% ahead of data readout for muscular dystrophy asset - MSN
Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - MSN
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy - Pharmaceutical Technology
US Bancorp DE Has $26,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Morgan Stanley Reiterates “Overweight” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World
Raymond James maintains $18 target on RGNX after trial data - Investing.com
Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive
Raymond James maintains $18 target on RGNX after trial data By Investing.com - Investing.com UK
REGENXBIO (NASDAQ:RGNX) Sees Strong Trading VolumeTime to Buy? - MarketBeat
What's Going On With REGENXBIO Shares Monday? - Benzinga
Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch
Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PR Newswire
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regenxbio Inc Stock (RGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Sale |
10.11 |
10,000 |
101,052 |
11,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Sale |
11.56 |
10,000 |
115,588 |
11,286 |
| Mills Kenneth T. | Director |
Aug 08 '24 |
Option Exercise |
0.85 |
36,316 |
30,869 |
444,351 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Option Exercise |
3.85 |
10,100 |
38,874 |
21,386 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Sale |
13.51 |
10,100 |
136,454 |
11,286 |
| Simpson Curran | Chief Executive Officer |
Aug 01 '24 |
Sale |
15.00 |
100 |
1,500 |
170,037 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):